Genelux (GNLX) Retained Earnings (2022 - 2026)
Genelux (GNLX) posted Retained Earnings of $315.8 million for Q1 2026, up 6.87% on a QoQ basis from $295.5 million in Q4 2025.
Analysis
Genelux (GNLX) Retained Earnings (2022 - 2026) Analysis & Trends
Genelux has reported Retained Earnings for 5 years, with the latest figure at $315.8 million in Q1 2026.
- On a quarterly basis, Retained Earnings changed N/A year-over-year to $315.8 million in Q1 2026; TTM through Mar 2026 was $315.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $295.5 million, up 6.28% from the prior year.
- Retained Earnings was $315.8 million for Q1 2026 at Genelux, up from $295.5 million in the prior quarter.
- The five-year high for Retained Earnings was $315.8 million in Q1 2026, with the low at -$189.8 million in Q4 2022.
- Average Retained Earnings over 5 years is $232.6 million, with a median of $275.8 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 227.19% in 2023, then advanced 6.06% in 2025.
- Over 5 years, Retained Earnings stood at -$189.8 million in 2022, then surged by 227.19% to $241.4 million in 2023, then increased by 15.17% to $278.0 million in 2024, then rose by 6.28% to $295.5 million in 2025, then advanced by 6.87% to $315.8 million in 2026.
- The last three Retained Earnings figures came in at $315.8 million (Q1 2026), $295.5 million (Q4 2025), and $293.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | 315.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 315.78 Mn |
| Dec 31, 2025 | 295.47 Mn |
| Sep 30, 2025 | 293.27 Mn |
| Jun 30, 2025 | 290.63 Mn |
| Dec 31, 2024 | 278.00 Mn |
| Sep 30, 2024 | 275.78 Mn |
| Jun 30, 2024 | 274.03 Mn |
| Mar 31, 2024 | 244.87 Mn |
| Dec 31, 2023 | 241.39 Mn |
| Sep 30, 2023 | 239.19 Mn |
| Dec 31, 2022 | -189.78 Mn |